About: biomedicines

IMI chief: ‘We need to learn how to share data in a safe and ethical manner’

Ethicists, humanists, lawyers and patients should come together to understand the risk of data in healthcare and whether patients are willing to take that risk, Pierre Meulien told EURACTIV.com.

Regulators pave way for new wave of biosimilar drugs in Europe

European regulators have cleared the way for the first serious threat to the makers of multibillion-euro biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.

Medicines in emerging markets

Fast-growing economies such as China and India could provide lucrative new markets for Europe's pharmaceutical industry, but emerging nations are investing heavily in their own medicines sector and look set to challenge Western dominance of the healthcare market.

‘Me’ medicine

Developments in biomedicine should be greeted with caution, writes Donna Dickenson, professor emeritus of medical ethics and humanities at the University of London, 2006 winner of the International Spinoza Lens Award for contributions to public debate on ethics and author of 'Body Shopping: The Economy Fuelled by Flesh and Blood'.

Biopharma’s capacity crunch

Dealmaking for Growth: How Biotech Firms Can Avoid the Tragedy of “Boom and Bust”

A cure for clinical trials

Splicing a cost squeeze into the genomics revolution